Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImmunoCellular Therapeutics, a biotechnology company, has signed a research agreement with UK-based biotechnology company Antitope for the humanization of IMUC's monoclonal antibodies.
Subscribe to our email newsletter
ImmunoCellular Therapeutics (IMUC) is advancing its monoclonal antibodies toward clinical trials, and humanizing the antibodies will provide for a safer therapeutic with less immunogenicity potential.
IMUC, through its recent acquisition of monoclonal antibody-related technology from Molecular Discoveries, has several novel monoclonal antibodies.
Manish Singh, president and CEO of IMUC, said: “We look forward to working with Antitope and believe that humanizing our antibodies is a key step in preparing these product candidates for human clinical trials, which we are targeting to initiate in 2010.”